COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
Rhea-AI Summary
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 26, 2025, before U.S. markets open.
The company will host a conference call at 10:00 a.m. EST to discuss financial results and corporate updates. Investors can participate using the following dial-in numbers:
- U.S. investors: 1-877-407-9716
- International investors: 1-201-493-6779
- Israel investors: 1-809-406-247
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLGN declined 1.66%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m.
REHOVOT,

Conference call information
To participate in the conference call, please use the dial-in information below:
U.S. investors: 1-877-407-9716
Investors outside of the
Conference ID: 13750725
Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the scheduled call start time:
https://callme.viavid.com/viavid/?callme=true&passcode=13728588&h=true&info=company-email&r=true&B=6
Webcast information
A live audio only webcast will also be available in listen-only mode and can be accessed here or via the link to be posted on the News & Events section of the CollPlant Investor relations website. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company's website for a limited time.
Submit questions to management in advance of the call
To ask management a question ahead of the call, please email Dan Ferry at LifeSci Advisors, LLC up until 24 hours before the event at daniel@lifesciadvisors.com.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on medical aesthetics and 3D bioprinting of tissues and organs. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Contacts
CollPlant: | Investor: |
Eran Rotem | Daniel Ferry |
Deputy CEO & CFO | Managing Director |
Tel: +972-73-2325600 | LifeSci Advisors, LLC |
Email: eran@collplant.com |
Logo - https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-2024-fourth-quarter-and-full-year-2024-financial-results-and-conference-call-information-302405677.html
SOURCE CollPlant